Clinical Trial Update: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

The Phase 1 study of WU-NK-101 in relapsed or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• WU-NK-101 (WU-NK-101)

Snippet

Sponsor: Wugen, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED